Emer Joyce, MB BCh BAO, PhD - Staying Ahead of the Curve in ATTR-CM: Adapting and Advancing Our Approach to Decision-Making as the Treatment Landscape Evolves

Raffaele Califano, MD - At the Frontline in ALK+ NSCLC: Practical Approaches to TKI Therapy

Raffaele Califano, MD - At the Frontline in ALK+ NSCLC: Practical Approaches to TKI Therapy...

2 years ago

18:24

Wisia Wedzicha, MD, FRCP - Taking the Evidence from Paper to Practice: Shared Perspectives on Practical Considerations in Comprehensive COPD Care

Wisia Wedzicha, MD, FRCP - Taking the Evidence from Paper to Practice: Shared Perspectives on Practical Considerations in Comprehensive COPD Care...

2 years ago

23:45

George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action

George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action...

2 years ago

11:16

David M. G. Halpin, MB BS, DPhil, FERS - The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of Disability and Death

David M. G. Halpin, MB BS, DPhil, FERS - The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of Disability and Death...

2 years ago

18:26

Perry Elliott, MD, FRCP - What’s New and What’s Next? Expanding Our Understanding of HCM in 2023

Perry Elliott, MD, FRCP - What’s New and What’s Next? Expanding Our Understanding of HCM in 2023...

2 years ago

24:37

Edward B. Garon, MD, MS - Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet Needs in NSCLC Without Actionable Mutations

Edward B. Garon, MD, MS - Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet Needs in NSCLC Without Actionable Mutations...

2 years ago

20:40

Claus Vogelmeier, MD - Approaching Airway Inflammation From Another Angle: The Rationale for Targeting Type 2 Pathways in COPD

Claus Vogelmeier, MD - Approaching Airway Inflammation From Another Angle: The Rationale for Targeting Type 2 Pathways in COPD...

2 years ago

20:54

Perry Elliott, MD, FRCP - Continuing Our Conversation in HCM: Compelling Questions and Evolving Considerations

Perry Elliott, MD, FRCP - Continuing Our Conversation in HCM: Compelling Questions and Evolving Considerations...

2 years ago

13:13

Laura Obici, MD - Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (ATTR): Shared Perspectives From Patients and Providers

Laura Obici, MD - Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (ATTR): Shared Perspectives From Patients and Providers...

2 years ago

38:10

Emer Joyce, MB BCh BAO, PhD - Staying Ahead of the Curve in ATTR-CM: Adapting and Advancing Our Approach to Decision-Making as the Treatment Landscape Evolves

PeerVoice Heart & Lung Audio